argenx announced that the FDA has accepted for priority review a sBLA for Vyvgart IV for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG), with a PDUFA target action date of 10 May 2026. The sBLA acceptance and priority review for Vyvgart in seronegative gMG brings argenx a step closer to its aim of having the broadest possible label in this setting. argenx estimates the commercial opportunity for seronegative gMG could add 1...
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART® (IV: efgartigimod alfa-fcab) for the treatment of adults with acetylcholine recepto...
Aedifica NV/SA: Publication relating to a transparency notification Aedifica NV/SA: Publication relating to a transparency notification Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding a publication relating to a transparency notification from BlackRock, Inc. Press release ENCommuniqué de presse FRPersbericht NL Attachments
argenx outlined its strategic priorities for 2026 and shared preliminary Vyvgart sales numbers coming in at $ 4.15b for FY25, more or less in line with CSS of $ 4.13b. Looking ahead, 2026 is set to be a catalyst rich year with 4 registrational readouts and we note that argenx provided more specific timeline guidance for each trial, while the earlier stage pipeline progresses with multiple new additions, and a biotech collaboration. We continue to see upside for the stock in 2026 and maintain our...
argenx Highlights 2026 Strategic Priorities Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026 Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches Successfully advanced four new pipeline molecules in 2025; three new molecules to enter Phase 1 in 2026, contr...
Aedifica NV/SA: Publication relating to a transparency notification Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding a publication relating to a transparency notification from BlackRock, Inc. Attachments
AB InBev: $3bn in the can; Aedifica: €108.5m investments at a 6-7% yield; Kinepolis: December US box office revenue down 2%, France visitors up 1%, Avatar below expectations; TomTom: Starting the year with CES fireworks; WDP: €58m investment in Le Havre and €35m disposal in Liège.
Galapagos announced that the previously reported works council consultation process regarding the wind-down of cell therapy activities has now been completed and its Board of Directors has decided to initiate the wind-down of the company's cell therapy activities. This decision follows a strategic review and sale process in 2025 where no viable offers emerged. We believe the wind-down creates clarity and, once completed, will allow management to move forward with their plan of building a new pip...
Aedifica announced € 108.5m new healthcare investments across Europe in a mixture of new forward funded developments, extensions and acquisitions. Aedifica still awaits the approval of the Belgian competition authorities (BCA) to open its exchange period. In our timeline, a decision is expected by 15/01. As a remedy, Aedifica suggested € 300.0m Belgian asset disposals in the coming years. As argued in earlier notes (See: better too early than sorry), Aedifica needs new investments at 6.5% net yi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.